Welcome to our dedicated page for Halozyme Therapeutics news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Therapeutics stock.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company headquartered in San Diego, CA, focused on developing and commercializing innovative oncology therapies. The company's core mission is to enhance the efficacy of cancer treatments by targeting the tumor microenvironment, particularly through its lead investigational drug, pegph20. This drug aims to improve the penetration of co-administered cancer therapies into solid tumors, potentially making existing treatments more effective.
Halozyme's proprietary ENHANZE® drug delivery technology platform has garnered significant attention and partnerships with leading pharmaceutical companies such as Roche, Pfizer, Janssen, Baxalta, AbbVie, and Lilly. This technology facilitates the subcutaneous administration of biologics and small molecule compounds that are traditionally delivered intravenously, potentially allowing for quicker and more convenient therapy delivery.
The company has built a strong foundation of value-driving partnerships and continues to innovate in drug-device combination products using advanced auto-injector technology to improve patient convenience, comfort, and adherence. Halozyme's commercial portfolio includes proprietary products like Hylenex® and XYOSTED®, and ongoing product development in partnership with pharmaceutical companies such as Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Recent achievements highlight Halozyme’s growth and innovation. Notably, the U.S. FDA approved Takeda’s HYQVIA®, co-formulated with ENHANZE®, for the maintenance therapy of chronic inflammatory demyelinating polyneuropathy (CIDP), underscoring the potential of Halozyme’s technology to enhance treatment efficacy. Another milestone includes the Japanese Ministry of Health's approval of argenx's VYVDURA® for generalized myasthenia gravis, demonstrating global expansion and acceptance of ENHANZE®-enabled treatments.
Financially, Halozyme continues to show robust growth. The company reported strong revenue and earnings growth in the first quarter of 2024, reaffirming its positive financial guidance for the year. Halozyme also announced a new $750 million share repurchase program, indicating confidence in sustained growth.
Halozyme's efforts in maintaining an extensive patent portfolio, including the recent grant of European Patent No. 4269578 for its ENHANZE® rHuPH20 product, further solidify its market position and prospects for long-term revenue durability. The company's strategic collaborations and commitment to innovative patient solutions make it a significant player in the biopharmaceutical industry.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will have its president and CEO, Dr. Helen Torley, present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT. The event will be accessible via a live audio webcast on the company's Investor Relations page, with replays available for 30 days. Halozyme is known for its innovative ENHANZE® technology, facilitating drug delivery for better patient outcomes and has impacted over 600,000 patients globally. The company also develops advanced drug-device combination products to enhance patient comfort and adherence.
Halozyme Therapeutics (NASDAQ: HALO) has announced participation in several upcoming investor conferences. Management, led by Dr. Helen Torley, will present at the J.P. Morgan Equity Opportunities Forum on November 15, 2022, in Miami, FL, and at the Piper Sandler Health Conference on November 30, 2022, in New York, NY, followed by the Evercore IS HealthCONx Conference on December 1, 2022, in a virtual format. Live webcasts of the events will be available on Halozyme's Investor Relations section.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported third quarter revenue of $209 million, up 80% year-over-year, with GAAP diluted EPS of $0.44 and non-GAAP diluted EPS of $0.74. Royalty revenue rose 70% year-over-year to $99.6 million. The company reiterated its 2022 revenue guidance of $655 million to $685 million, anticipating 48%-55% growth compared to 2021. Key advancements include regulatory submissions for ENHANZE® products. Cash and equivalents stood at $265.6 million as of September 30, 2022.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the release of its third quarter 2022 financial and operating results on November 8, 2022, after the market closes. A conference call will follow at 4:30 p.m. ET to discuss these results. Interested parties can register for the call here, and a live webcast will also be available on Halozyme's investor relations site. Halozyme, known for its ENHANZE® technology, aims to enhance patient experiences through innovative biopharmaceutical solutions.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced Dr. Helen Torley's participation at the 2022 Wells Fargo Healthcare Conference from September 7-9, 2022, in Boston, MA. Dr. Torley will present on September 8 at 5:35 a.m. PT / 8:35 a.m. ET, alongside hosting investor meetings. A live audio webcast of the presentation will be available on the Company’s Investor Relations section, with replays accessible for 90 days post-conference. Halozyme is renowned for its ENHANZE® technology, enhancing drug delivery and improving patient experiences.
Halozyme Therapeutics (NASDAQ: HALO) announced the pricing of a $625 million offering of convertible senior notes due 2028, upsized from an initial $500 million. The notes will bear an interest rate of 1.00% and are convertible at a rate of 17.8517 shares per $1,000 principal amount, equating to an initial conversion price of $56.02. Proceeds of approximately $608.7 million will be used for capped call transactions, repurchasing existing convertible notes, and share repurchases, among other corporate purposes, set to close on August 18, 2022.
Halozyme Therapeutics plans a $500 million offering of convertible senior notes due 2028, subject to market conditions, with an option for an additional $75 million. The company intends to use proceeds for capped call transactions, repurchasing shares up to $200 million, and repaying a $250 million term loan due 2026. The offering could potentially influence the market price of Halozyme's common stock.
Halozyme Therapeutics (HALO) announced its second quarter financial results for 2022, reporting a revenue increase of 12% year-over-year to $152.4 million. GAAP diluted EPS was $0.16, while non-GAAP EPS reached $0.53. The company raised its full-year revenue guidance to $655 million to $685 million, driven by strong royalty growth of 86% to $85.3 million and the recent acquisition of Antares Pharma. However, projected operating income and GAAP net income guidance decreased significantly due to acquisition-related costs. Halozyme remains optimistic about future growth with multiple upcoming product launches.
Halozyme Therapeutics (NASDAQ: HALO) announced positive results from Roche's Phase III IMscin001 study, evaluating a subcutaneous formulation of Tecentriq® using ENHANZE® technology. The study demonstrated non-inferior pharmacokinetics of Tecentriq when delivered subcutaneously compared to intravenous infusion in patients with advanced non-small cell lung cancer. Treatment time was significantly reduced to 3-8 minutes versus 30-60 minutes for IV. Roche plans to submit data for global regulatory approval.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it will release its second quarter 2022 financial results on August 9, 2022, after market close. A conference call will follow at 4:30 p.m. ET with dial-in numbers provided for both domestic and international callers. Halozyme is recognized for its ENHANZE® technology, enhancing drug delivery. With over 600,000 patients impacted, it has commercial products and partnerships with major pharmaceutical companies. For more details, visit www.halozyme.com.
FAQ
What is the current stock price of Halozyme Therapeutics (HALO)?
What is the market cap of Halozyme Therapeutics (HALO)?
What is Halozyme Therapeutics' main focus?
What is the ENHANZE® technology?
Who are Halozyme's key partners?
What recent approvals have Halozyme's technologies received?
What are some of Halozyme's proprietary products?
Where is Halozyme headquartered?
How does Halozyme's ENHANZE® technology benefit patients?
What is the significance of Halozyme's recent European patent grant?
What financial outlook did Halozyme recently provide?
What is pegph20?
